Alaunos Therapeutics, Inc. Unrealized Gain (Loss) on Derivatives
Alaunos Therapeutics, Inc. (TCRT) reported Unrealized Gain (Loss) on Derivatives of -$3.53 million for the 3-month period ending 2016-12-31, per its 10-K filed 2017-02-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2017-02-16
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2016-12-31 was -$3.53M.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2016-09-30 was -$3.59M.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2014-12-31 was $194.00K.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2014-09-30 was $5.85M.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2014 was $11.72M, a 889.28% increase from fiscal 2013.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2013 was $1.19M, a 80.41% decline from fiscal 2012.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2012 was $6.05M, a 20.22% decline from fiscal 2011.
- Alaunos Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2011 was $7.58M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month | Unrealized Gain (Loss) on Derivatives 124 month | Unrealized Gain (Loss) on Derivatives 127 month |
|---|---|---|---|---|---|---|
| 2016-12-31 | -$3.53M 10-K · filed 2017-02-16 | -$7.12M derived: sum of 2 quarters · filed 2017-02-16 | ||||
| 2016-09-30 | -$3.59M 10-K · filed 2017-02-16 | |||||
| 2014-12-31 | $194.00K 10-K · filed 2016-02-24 | $6.04M derived: sum of 2 quarters · filed 2016-02-24 | $11.64M derived: sum of 3 quarters · filed 2016-02-24 | $11.72M 10-K · filed 2017-02-16 | ||
| 2014-09-30 | $5.85M 10-K · filed 2016-02-24 | $11.45M derived: sum of 2 quarters · filed 2016-02-24 | $11.53M 10-Q · filed 2015-11-02 | $9.74M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-30 | $5.60M 10-K · filed 2016-02-24 | $5.68M 10-Q · filed 2015-08-10 | $3.89M derived: sum of 3 quarters · filed 2016-02-24 | -$3.52M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-31 | $82.00K 10-K · filed 2016-02-24 | -$1.71M derived: sum of 2 quarters · filed 2016-02-24 | -$9.12M derived: sum of 3 quarters · filed 2016-02-24 | -$9.52M derived: sum of 4 quarters · filed 2016-02-24 | $12.04M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | -$1.79M 10-K · filed 2015-02-26 | -$9.20M derived: sum of 2 quarters · filed 2015-02-26 | -$9.60M derived: sum of 3 quarters · filed 2015-02-26 | $1.19M 10-K · filed 2016-02-24 | $11.96M 10-K · filed 2014-03-03 | |
| 2013-09-30 | -$7.41M 10-K · filed 2015-02-26 | -$7.81M derived: sum of 2 quarters · filed 2015-02-26 | $2.98M 10-Q · filed 2014-10-30 | $11.54M derived: sum of 4 quarters · filed 2015-02-26 | ||
| 2013-06-30 | -$403.00K 10-Q · filed 2014-08-07 | $10.38M 10-Q · filed 2014-08-07 | $18.95M derived: sum of 3 quarters · filed 2015-02-26 | $22.90M derived: sum of 4 quarters · filed 2015-02-26 | ||
| 2013-03-31 | $10.79M 10-K · filed 2015-02-26 | $19.35M derived: sum of 2 quarters · filed 2015-02-26 | $23.30M derived: sum of 3 quarters · filed 2015-02-26 | $22.65M derived: sum of 4 quarters · filed 2015-02-26 | ||
| 2012-12-31 | $8.57M 10-K · filed 2014-03-03 | $12.51M derived: sum of 2 quarters · filed 2014-03-03 | $11.86M derived: sum of 3 quarters · filed 2014-03-03 | $6.05M 10-K · filed 2015-02-26 | ||
| 2012-09-30 | $3.94M 10-K · filed 2014-03-03 | $3.29M derived: sum of 2 quarters · filed 2014-03-03 | -$2.52M derived: sum of 3 quarters · filed 2014-03-03 | |||
| 2012-06-30 | -$650.00K 10-K · filed 2014-03-03 | -$6.46M derived: sum of 2 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | -$5.81M 10-K · filed 2014-03-03 | |||||
| 2011-12-31 | $7.58M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |